Skip to main content

Advertisement

SpringerLink
Log in

Bone Marrow Mesenchymal Stem Cell Therapy and Related Bone Marrow-Derived Orthobiologic Therapeutics

  • Stem Cells in Orthopaedic Surgery (J Dragoo and K Jones, Section Editors)
  • Published:
Current Reviews in Musculoskeletal Medicine Aims and scope Submit manuscript

Abstract

Purpose of Review

The purpose of the current article is to review the available literature related to bone marrow-derived mesenchymal stem cell therapy in the management of musculoskeletal pathologies and demonstrate the critical need for additional well-designed clinical studies.

Recent Findings

In recent years, there has been a rapid increase in interest regarding the use of bone marrow-derived mesenchymal stem cells in the treatment of musculoskeletal injury and disease. The clinical use of BM-MSCs and other forms of stem cell therapy has far outpaced the basic and translational science evidence required to elucidate the potential efficacy of this orthobiologic treatment approach. Early studies have demonstrated potential clinical benefit of utilizing bone marrow-derived mesenchymal stem cell therapy in the management of knee osteoarthritis, focal chondral lesions, shoulder pathology including rotator cuff tears and glenohumeral arthritis, and degenerative disk disease in the spine. To date, most published studies are small case series often lacking a control group or a standardized method of treatment.

Summary

Bone marrow-derived mesenchymal stem cell therapy is becoming an increasingly common treatment for musculoskeletal injuries and disease. Although early clinical studies have shown promising outcomes, methodological flaws and lack of standardization among trials have limited the conclusions that can be drawn from the existing literature. A better understanding of the underlying mechanism of action and more carefully designed clinical trials will help reveal the efficacy and utility of BM-MSCs as a treatment modality for various orthopedic pathologies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641–50. https://doi.org/10.1002/jor.1100090504.

    Article  CAS  PubMed  Google Scholar 

  2. Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: a pluripotent population with multiple applications. Curr Stem Cell Res Ther. 2006;1(3):365–9.

    Article  CAS  PubMed  Google Scholar 

  3. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science (New York, NY). 1999;284(5411):143–7.

    Article  CAS  Google Scholar 

  4. Bruder SP, Fink DJ, Caplan AI. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem. 1994;56(3):283–94. https://doi.org/10.1002/jcb.240560303.

    Article  CAS  PubMed  Google Scholar 

  5. Pean CA, Kingery MT, Strauss E, Bosco J, Halbrecht J. Direct to consumer advertising of stem cell clinics: ethical considerations and recommendations for the healthcare community. The Journal of bone and joint surgery American volume. 2019;In Press.

  6. FTC stops deceptive health claims by a stem cell therapy clinic. Federal Trade Commission. 2018. https://www.ftc.gov/news-events/press-releases/2018/10/ftc-stops-deceptive-health-claims-stem-cell-therapy-clinic. 2019.

  7. • McIntyre JA, Jones IA, Han B, Vangsness CT Jr. Intra-articular mesenchymal stem cell therapy for the human joint: a systematic review. Am J Sports Med. 2018;46(14):3550–63. https://doi.org/10.1177/0363546517735844The authors, researchers at the Keck School of Medicine, performed a systematic review to provide a comprehensive overview of the current human literature investigating the safety and efficacy of intra-articular mesenchymal stem cell (MSC) therapy in all joints. They found that while intra-articular mesenchymal stem cell therapy is safe, the overall quality of the literature was poor, and the heterogeneity of measured outcomes made it difficult draw firm conclusions regarding the efficacy of these treatments. This is in agreement with a more recently published study by Pean et al. cited below which acknowledges the safety of the therapy but cautions the public to consider the limited amount of evidence supporting the efficacy of the therapy.

    Article  PubMed  Google Scholar 

  8. Hernigou P, Flouzat Lachaniette CH, Delambre J, Zilber S, Duffiet P, Chevallier N, et al. Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study. Int Orthop. 2014;38(9):1811–8. https://doi.org/10.1007/s00264-014-2391-1.

    Article  PubMed  Google Scholar 

  9. • Garay-Mendoza D, Villarreal-Martinez L, Garza-Bedolla A, Perez-Garza DM, Acosta-Olivo C, Vilchez-Cavazos F, et al. The effect of intra-articular injection of autologous bone marrow stem cells on pain and knee function in patients with osteoarthritis. Int J Rheum Dis. 2018;21(1):140–7. https://doi.org/10.1111/1756-185x.13139The authors, researchers from the Autonomous University of Nuevo Leon, used intra-articular injections of autologous stimulated bone marrow stem cells in patients with knee osteoarthritis, in a prospective, open-label, phase I/II clinical trial to assess its safety and efficacy. They hypothesized that a single intra-articular injection in vivo of stimulated bone marrow stem cells could lead to an improvement in pain management and quality of life in patients with knee OA. They found their hypothesis supported by 6-month follow-up data, in which the experimental arm reported significant improvement in knee pain and quality of life.

    Article  CAS  PubMed  Google Scholar 

  10. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7. https://doi.org/10.1080/14653240600855905.

    Article  CAS  PubMed  Google Scholar 

  11. • Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med. 2017;6(6):1445–51. https://doi.org/10.1002/sctm.17-0051The author, a researcher at Case Western Reserve University, reviewed the transformation of the term “mesenchymal stem cell” from its discovery to current day. He acknowledged that the initial definition of the phrase referred to bone marrow and periosteum that could be isolated and expanded in culture while maintaining their in vitro capacity to be induced to form a variety of mesodermal phenotypes and tissues; however, he then argued that the definition has been contorted in modern day literature to infer clinically beneficial properties despite lacking a strong scientific backing. This was validated by several studies, cited below, that interchange terms including (but not limited to) “stem cells,” “bone marrow aspirate concentrate,” and “bone marrow cells”.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Muraglia A, Corsi A, Riminucci M, Mastrogiacomo M, Cancedda R, Bianco P, et al. Formation of a chondro-osseous rudiment in micromass cultures of human bone-marrow stromal cells. J Cell Sci. 2003;116(Pt 14):2949–55. https://doi.org/10.1242/jcs.00527.

    Article  CAS  PubMed  Google Scholar 

  13. Caplan AI. All MSCs are pericytes? Cell Stem Cell. 2008;3(3):229–30. https://doi.org/10.1016/j.stem.2008.08.008.

    Article  CAS  PubMed  Google Scholar 

  14. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3(3):301–13. https://doi.org/10.1016/j.stem.2008.07.003.

    Article  CAS  PubMed  Google Scholar 

  15. • Guimaraes-Camboa N, Cattaneo P, Sun Y, Moore-Morris T, Gu Y, Dalton ND, et al. Pericytes of Multiple Organs Do Not Behave as Mesenchymal Stem Cells In Vivo. Cell Stem Cell. 2017;20(3):345–59.e5. https://doi.org/10.1016/j.stem.2016.12.006The authors, researchers from the University of California at San Diego and the University of Porto, used pericytes and vascular smooth muscle cells from multiple organs of adult mice to test their hypothesis that pericytes did not behave as stem cells. Through permanent labeling of these pericytes and vascular smooth muscle cells, the authors tracked the fate of these cells and showed that, in vivo, pericytes did not behave as stem cells. This challenged the previously held view of pericytes as tissue-resident multipotent progenitors.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lin P, Correa D, Kean TJ, Awadallah A, Dennis JE, Caplan AI. Serial transplantation and long-term engraftment of intra-arterially delivered clonally derived mesenchymal stem cells to injured bone marrow. Mol Ther. 2014;22(1):160–8. https://doi.org/10.1038/mt.2013.221.

    Article  CAS  PubMed  Google Scholar 

  17. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98(5):1076–84. https://doi.org/10.1002/jcb.20886.

    Article  CAS  PubMed  Google Scholar 

  18. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20(5-6):419–27. https://doi.org/10.1016/j.cytogfr.2009.10.002.

    Article  CAS  PubMed  Google Scholar 

  19. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013;45:e54. https://doi.org/10.1038/emm.2013.94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007;131(2):324–36. https://doi.org/10.1016/j.cell.2007.08.025.

    Article  CAS  PubMed  Google Scholar 

  21. Au P, Tam J, Fukumura D, Jain RK. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood. 2008;111(9):4551–8. https://doi.org/10.1182/blood-2007-10-118273.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ozeki N, Muneta T, Koga H, Nakagawa Y, Mizuno M, Tsuji K, et al. Not single but periodic injections of synovial mesenchymal stem cells maintain viable cells in knees and inhibit osteoarthritis progression in rats. Osteoarthr Cartil. 2016;24(6):1061–70. https://doi.org/10.1016/j.joca.2015.12.018.

    Article  CAS  Google Scholar 

  23. Wolfstadt JI, Cole BJ, Ogilvie-Harris DJ, Viswanathan S, Chahal J. Current concepts: the role of mesenchymal stem cells in the management of knee osteoarthritis. Sports Health. 2015;7(1):38–44. https://doi.org/10.1177/1941738114529727.

    Article  PubMed  PubMed Central  Google Scholar 

  24. • Jones IA, Chen X, Evseenko D, Vangsness CT Jr. Nomenclature inconsistency and selective outcome reporting hinder understanding of stem cell therapy for the knee. J Bone Joint Surg Am. 2019;101(2):186–95. https://doi.org/10.2106/jbjs.17.01474The authors, researchers from the University of California Irvine School of Medicine and Keck School of Medicine, performed a review of randomized clinical trials that addressed two areas they believed had been overlooked: nomenclature inconsistency and selective outcome reporting. They found significant heterogeneity in treatments, adjuvant therapies, and outcome measures. Additionally, they suggested that papers with generally positive efficacy conclusions concerning stem cell therapy for knee cartilage pathology may have been overstated. In concordance with the review performed by McIntyre et al., cited above, the authors recommended that clinicians should consider current cell-based therapies independently, rather than seeing them as belonging to a larger class of “mesenchymal stem cell” and/or “stem cell” therapies.

    Article  PubMed  Google Scholar 

  25. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use. U.S. Food and Drug Administration, Services USDoHaH; December 2017.

  26. Centeno C, Busse D, Kisiday J, Keohan C, Freeman M, Karli D. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Phys. 2008;11(3):343–53.

    Google Scholar 

  27. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis. 2011;14(2):211–5. https://doi.org/10.1111/j.1756-185X.2011.01599.x.

    Article  PubMed  Google Scholar 

  28. Davatchi F, Sadeghi Abdollahi B, Mohyeddin M, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis: 5 years follow-up of three patients. Int J Rheum Dis. 2016;19(3):219–25. https://doi.org/10.1111/1756-185X.12670.

    Article  PubMed  Google Scholar 

  29. Emadedin M, Aghdami N, Taghiyar L, Fazeli R, Moghadasali R, Jahangir S, et al. Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. Arch Iran Med. 2012;15(7):422–8.

    PubMed  Google Scholar 

  30. Emadedin M, Ghorbani Liastani M, Fazeli R, Mohseni F, Moghadasali R, Mardpour S, et al. Long-term follow-up of intra-articular injection of autologous mesenchymal stem cells in patients with knee, ankle, or hip osteoarthritis. Arch Iran Med. 2015;18(6):336–44.

    PubMed  Google Scholar 

  31. Orozco L, Munar A, Soler R, Alberca M, Soler F, Huguet M, et al. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. Transplantation. 2013;95(12):1535–41. https://doi.org/10.1097/TP.0b013e318291a2da.

    Article  CAS  PubMed  Google Scholar 

  32. Orozco L, Munar A, Soler R, Alberca M, Soler F, Huguet M, et al. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: two-year follow-up results. Transplantation. 2014:e66–8.

    Article  PubMed  Google Scholar 

  33. Vega A, Martín-Ferrero M, Del Canto F, Alberca M, García V, Munar A, et al. Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation. 2015;99(8):1681–90. https://doi.org/10.1097/TP.0000000000000678.

    Article  CAS  PubMed  Google Scholar 

  34. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthr Cartil. 2002;10(3):199–206. https://doi.org/10.1053/joca.2001.0504.

    Article  CAS  Google Scholar 

  35. Wakitani S, Nawata M, Tensho K, Okabe T, Machida H, Ohgushi H. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. J Tissue Eng Regen Med. 2007;1:74–9. https://doi.org/10.1002/term.8.

    Article  PubMed  Google Scholar 

  36. Nejadnik H, Hui J, Feng Choong E, Tai B, Lee E. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am J Sports Med. 2010;38(6):1110–6. https://doi.org/10.1177/0363546509359067.

    Article  PubMed  Google Scholar 

  37. Haleem A, Singergy A, Sabry D, Atta H, Rashed L, Chu C, et al. The clinical use of human culture-expanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects: a pilot study and preliminary results. Cartilage. 2010;1(4):253–61. https://doi.org/10.1177/1947603510366027.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Wong K, Lee K, Tai B, Law P, Lee E, Hui J. Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years’ follow-up. Arthroscopy. 2013;29(12):2020–8. https://doi.org/10.1016/j.arthro.2013.09.074.

    Article  PubMed  Google Scholar 

  39. Stein BE, Stroh DA, Schon LC. Outcomes of acute Achilles tendon rupture repair with bone marrow aspirate concentrate augmentation. Int Orthop. 2015;39(5):901–5. https://doi.org/10.1007/s00264-015-2725-7.

    Article  PubMed  Google Scholar 

  40. Singh A, Gangwar DS, Singh S. Bone marrow injection: a novel treatment for tennis elbow. J Nat Sci Biol Med. 2014;5(2):389–91. https://doi.org/10.4103/0976-9668.136198.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Centeno CJ, Al-Sayegh H, Bashir J, Goodyear S, Freeman MD. A prospective multi-site registry study of a specific protocol of autologous bone marrow concentrate for the treatment of shoulder rotator cuff tears and osteoarthritis. J Pain Res. 2015;8:269–76. https://doi.org/10.2147/JPR.S80872.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Gessmann J, Koller M, Godry H, Schildhauer TA, Seybold D. Regenerate augmentation with bone marrow concentrate after traumatic bone loss. Orthop Rev (Pavia). 2012;4(1):e14. https://doi.org/10.4081/or.2012.e14.

    Article  PubMed Central  Google Scholar 

  43. Petri M, Namazian A, Wilke F, Ettinger M, Stubig T, Brand S, et al. Repair of segmental long-bone defects by stem cell concentrate augmented scaffolds: a clinical and positron emission tomography--computed tomography analysis. Int Orthop. 2013;37(11):2231–7. https://doi.org/10.1007/s00264-013-2087-y.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Pascual-Garrido C, Rolon A, Makino A. Treatment of chronic patellar tendinopathy with autologous bone marrow stem cells: a 5-year-followup. Stem Cells Int. 2012;2012:953510. https://doi.org/10.1155/2012/953510.

    Article  PubMed  Google Scholar 

  45. Centeno CJ, Pitts J, Al-Sayegh H, Freeman MD. Anterior cruciate ligament tears treated with percutaneous injection of autologous bone marrow nucleated cells: a case series. J Pain Res. 2015;8:437–47. https://doi.org/10.2147/JPR.S86244.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Gangji V, De Maertelaer V, Hauzeur JP. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: Five year follow-up of a prospective controlled study. Bone. 2011;49(5):1005–9. https://doi.org/10.1016/j.bone.2011.07.032.

    Article  PubMed  Google Scholar 

  47. Tabatabaee RM, Saberi S, Parvizi J, Mortazavi SM, Farzan M. Combining concentrated autologous bone marrow stem cells injection with core decompression improves outcome for patients with early-stage osteonecrosis of the femoral head: a comparative study. J Arthroplast. 2015;30(9 Suppl):11–5. https://doi.org/10.1016/j.arth.2015.06.022.

    Article  Google Scholar 

  48. Pepke W, Kasten P, Beckmann NA, Janicki P, Egermann M. Core decompression and autologous bone marrow concentrate for treatment of femoral head osteonecrosis: a randomized prospective study. Orthop Rev (Pavia). 2016;8(1):6162. https://doi.org/10.4081/or.2016.6162.

    Article  Google Scholar 

  49. Giannini S, Buda R, Vannini F, Cavallo M, Grigolo B. One-step bone marrow-derived cell transplantation in talar osteochondral lesions. Clin Orthop Relat Res. 2009;467(12):3307–20. https://doi.org/10.1007/s11999-009-0885-8.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Buda R, Vannini F, Cavallo M, Baldassarri M, Natali S, Castagnini F, et al. One-step bone marrow-derived cell transplantation in talarosteochondral lesions: mid-term results. Joints. 2013;1(3):102–7.

    Article  PubMed  Google Scholar 

  51. Pettine KA, Murphy MB, Suzuki RK, Sand TT. Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months. Stem Cells (Dayton, Ohio). 2015;33(1):146–56. https://doi.org/10.1002/stem.1845.

    Article  CAS  Google Scholar 

  52. Pettine K, Suzuki R, Sand T, Murphy M. Treatment of discogenic back pain with autologous bone marrow concentrate injection with minimum two year follow-up. Int Orthop. 2016;40(1):135–40. https://doi.org/10.1007/s00264-015-2886-4.

    Article  PubMed  Google Scholar 

  53. Hart R, Komzak M, Okal F, Nahlik D, Jajtner P, Puskeiler M. Allograft alone versus allograft with bone marrow concentrate for the healing of the instrumented posterolateral lumbar fusion. Spine J. 2014;14(7):1318–24. https://doi.org/10.1016/j.spinee.2013.12.014.

    Article  PubMed  Google Scholar 

  54. Piuzzi NS, Hussain ZB, Chahla J, Cinque ME, Moatshe G, Mantripragada VP, et al. Variability in the preparation, reporting, and use of bone marrow aspirate concentrate in musculoskeletal disorders: a systematic review of the clinical orthopaedic literature. J Bone Joint Surg Am. 2018;100(6):517–25. https://doi.org/10.2106/jbjs.17.00451.

    Article  PubMed  Google Scholar 

  55. Chu CR, Rodeo S, Bhutani N, Goodrich LR, Huard J, Irrgang J, et al. Optimizing clinical use of biologics in orthopaedic surgery: consensus recommendations from the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg. 2019;27(2):e50–63. https://doi.org/10.5435/jaaos-d-18-00305.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Joanne Halbrecht, MD for providing her expertise on mesenchymal stem cell therapies.

Author information

Authors and Affiliations

  1. Division of Sports Medicine, Department of Orthopedic Surgery, NYU Langone Health, New York, NY, USA

    Matthew T. Kingery, Amit K. Manjunath, Utkarsh Anil & Eric J. Strauss

  2. NYU Langone Orthopedics, 333 East 38th Street, 4th Floor, New York, NY, 10016, USA

    Eric J. Strauss

Authors
  1. Matthew T. Kingery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amit K. Manjunath
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Utkarsh Anil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eric J. Strauss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric J. Strauss.

Ethics declarations

Conflict of Interest

Matthew Kingery, Amit Manjunath, and Utkarsh Anil declare that they have no conflicts of interest. Eric Strauss serves as a paid consultant to Arthrex and Organogenesis.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Stem Cells in Orthopaedic Surgery

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kingery, M.T., Manjunath, A.K., Anil, U. et al. Bone Marrow Mesenchymal Stem Cell Therapy and Related Bone Marrow-Derived Orthobiologic Therapeutics. Curr Rev Musculoskelet Med 12, 451–459 (2019). https://doi.org/10.1007/s12178-019-09583-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12178-019-09583-1

Keywords

Search

Navigation